LSR and diabetes mellitus: This review will explore antioxidative, Nrf2-involving treatments targeting different risk factors of diabetic dyslipidemia (e.g., VLDL, sdLDL, hepatic lipolysis-stimulated lipoprotein receptor (LSR) impairment), how each of the risk factors causes atherosclerosis, and how the treatments can therefore be used to treat atherosclerosis in patients with DM.